Skip to main navigation

Contact Us

Investor Relations

Our Company
Product Candidates
- Pipeline
- MultiTAA Therapies
Our Science
Clinical Trials
- Active Clinical Trials
- Expanded Access Policy
Investors/Media
Careers

Investors/Media

Press Releases

Press Releases

Year

Nov 12, 2019

Marker Therapeutics Reports Third Quarter 2019 Operating and Financial Results

Nov 11, 2019

Marker Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast on Tuesday, November 12, 2019

Aug 15, 2019

Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs

Aug 08, 2019

Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Aug 06, 2019

Marker Therapeutics Appoints Steve Elms to its Board of Directors

Jul 20, 2019

Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

Jul 17, 2019

Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma

Jun 20, 2019

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

May 21, 2019

Marker Therapeutics to Present at Two Upcoming Investor Conferences

May 09, 2019

Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results

Pagination

First page
Previous page
…
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Next page
Last page

Displaying 81 - 90 of 109

Investors/Media

Investors/Media Home
News & Events
- Press Releases
- Events & Presentations
Stock Information
Financials & Filings
Corporate Governance
Investor Resources

IR and Media Contacts

investor.relations@markertherapeutics.com
(713) 400-6400

©2024 Marker Therapeutics, Inc. All Rights Reserved.

Footer Links

Sitemap
Terms of Use
Privacy Policy